Every material Form 8-K WW INTERNATIONAL, INC. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
WW International reported third-quarter 2026 results on November 5, 2026. Revenue fell 11% year-over-year to $152.9 million, while net income was $15.1 million versus a net loss of $57.5 million a year earlier, and Adjusted EBITDA rose 21% to $51.7 million. The company narrowed its full-year 2026 revenue guidance to $625 million to $630 million and its Adjusted EBITDA guidance to $110 million to $115 million, so shareholders see a mix of lower sales and improved profit.
Q3 revenue was $152.9 million, down 11% year-over-year; Clinical Subscription Revenue rose 48% to $38.0 million.
Q3 net income was $15.1 million, or $1.51 per diluted share, compared with a net loss of $57.5 million in Q3 2025.
Full-year 2026 revenue guidance narrowed to $625 million to $630 million from $620 million to $635 million.
Full-year 2026 Adjusted EBITDA guidance narrowed to $110 million to $115 million from $105 million to $115 million.
WW International appointed Stephen J. Bye as President and Chief Executive Officer and as a director, with his start date to be set on or before November 27, 2026. Bye most recently led Ookla, and the filing discloses his employment terms, including a $850,000 base salary and a $1,500,000 signing bonus. The interim office led by the CFO and Chief Operations Officer will dissolve when he starts.
Start date is on or before November 27, 2026, as mutually agreed; the Board increases from six to seven directors on that date.
Base salary is $850,000, with a target bonus of 125% of base salary and a $1,500,000 signing bonus paid in 2027 and 2028.
Initial grant has a value of $5,100,000 and is expected in or after January 2027; severance includes two times base salary plus target bonus on a change in control.
Interim Office of the Chief Executive, formed April 3, 2026, dissolves on his start date; CFO Felicia DellaFortuna and Chief Operations Officer Jonathan Volkmann keep their current titles.
WW International reported second-quarter 2026 revenue of $162.3 million, down 14.2% from the combined prior-year period, while Clinical Subscription Revenue rose 30.4% year-over-year. The company reported Q2 net income of $14.1 million and reaffirmed full-year 2026 revenue guidance of $620 million to $635 million and Adjusted EBITDA guidance of $105 million to $115 million.
Q2 2026 revenue of $162.3 million versus $189.2 million combined for Q2 2025, a 14.2% decline; Behavioral Subscription Revenue fell 22.7%
Q2 2026 net income of $14.1 million; Adjusted EBITDA of $39.8 million
Full-year 2026 guidance reaffirmed: revenue $620 million to $635 million; Adjusted EBITDA $105 million to $115 million
Term loan principal reduced by $41.4 million in Q2 2026, cutting annualized interest expense by about $4 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every WW INTERNATIONAL, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →